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Abstract 
 
The hepatitis B virus (HBV) envelope protein (S) self-assembles into subviral particles 
used as commercial vaccines against hepatitis B. These particles are excellent carriers 
for foreign epitopes, which can be inserted into the external hydrophilic loop or at the N- 
or C-terminal end of the HBV S protein. We show here that the N-terminal 
transmembrane domain (TMD) of HBV S can be replaced by the TMDs of the hepatitis 
C virus (HCV) envelope proteins E1 and E2, to generate fusion proteins containing the 
entire HCV E1 or E2 sequence that are efficiently coassembled with the HBV S into 
particles. This demonstrates the remarkable tolerance of the HBV S protein to sequence 
substitutions conserving its subviral particle assembly properties. These findings may 
have implications for the design of new vaccine strategies based on the use of HBV 
subviral particles as carriers for various transmembrane proteins and produced with 
the same industrial procedures established for the HBV vaccine. 
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Introduction 
 
Many viral structural proteins are intrinsically able to assemble into virus-like particles 
independently of viral nucleic acids. Antigens present as multiple copies on these virus-like 
particles are effective immunogens, and can elicit potent anti-viral humoral and cellular 
immune responses against the viruses from which they are derived [1, 2]. In particular, the 
small (S) envelope protein of the hepatitis B virus (HBV) self-assembles into highly 
immunogenic, non-infectious subviral particles [3]. The HBV S protein produced in 
mammalian cells is secreted as a 22-nm subviral particles which has over the last 25 years 
been used worldwide as a commercial hepatitis B vaccine. As these HBV subviral envelope 
particles provide a safe antigen delivery system, they have also long been used as a carrier for 
the presentation of various antigen epitopes. The epitopes presented in this way have included 
those of the capsid protein of poliovirus [4, 5], the hepatitis C virus (HCV) envelope proteins 
[6, 7], the human immunodeficiency virus envelope proteins [8-11] and the malaria parasite 
[12]. According to the current model, the HBV S protein is an intrinsic membrane protein of 
226 amino-acids - aa - (adw subtype) that spans the endoplasmic reticulum (ER) membrane 
four times (Fig. 1) [13-15]. This model predicts the exposure of the amino-terminal (N-
terminal) and carboxyl-terminal (C-terminal) ends and of a short hydrophilic loop (also 
known as the antigenic loop) in the middle of the protein to the ER lumen and at the surface 
of the subviral particle after particle budding. The insertion of small foreign sequences into 
the luminal loop of the HBV S protein has been shown to be compatible with particle 
formation [4, 5, 7, 9, 11, 16]. The N-terminal ectodomain [10, 12] and the C-terminal [8] 
ectodomains of HBV S protein also tolerate the insertion of foreign residues, with no effect on 
particle formation. A study investigating the incorporation of green fluorescent protein (GFP) 
into various domains of the HBV S protein demonstrated that the N-terminal ectodomain of 
HBV S was more permissive for insertions than the C-terminal ectodomain [17]. 
 
However, none of these previous studies was designed to incorporate a foreign protein, 
including its transmembrane domain, into the HBV subviral envelope particle. As the HBV S 
protein can tolerate major modifications without deleterious effects on self-assembly into 
subviral particles, we decided to address this question. We chose to use the HCV E1 and E2 
envelope proteins as models for this approach for three major reasons:  
 
(i) HCV is a member of the Flaviviridae family and it is an important human 
pathogen. Its envelope proteins E1 and E2 constitute a potential target for the development of 
a prophylactic HCV vaccine, as they are probably involved in virus-host recognition and 
antibodies directed against these proteins seem to neutralize HCV [18]. 
 
(ii) Both these proteins have a single transmembrane domain resulting in their 
retention in the ER membrane (Fig. 1), and preventing their purification [19]. Subviral 
envelope particles lacking a core are observed in other flavivirus infections, but no subviral 
HCV envelope particles have been described in the serum of infected patients, and it is not 
possible to generate such particles by producing HCV E1 and E2 proteins in cell lines [20]. 
The production of HCV envelope proteins as secreted recombinant proteins for vaccine 
development requires the deletion of the transmembrane domain. However, these truncated 
forms remain however difficult to purify, requiring the use of processes incompatible with 
industrial developments [21]. Furthermore, the truncation of these proteins by deletion of their 
transmembrane domain has been shown to impair their antigenic and functional properties 
[22]. 
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(iii)This strategy could potentially lead to the development of a bivalent HBV-HCV 
prophylactic vaccine candidate of potential interest as the populations at risk of infection with 
these two viruses are essentially the same [18]. 
 
We thus designed chimeric HBV-HCV envelope proteins in which the HCV E1 or E2 
protein was fused to the HBV S protein. The N-terminal transmembrane domain of the HBV 
S was replaced by the transmembrane domain of the HCV E1 or E2 protein, to preserve the 
integrity of the HCV E1 or E2 proteins, and to maintain the chimeric proteins in an 
appropriate membrane topology. We found that the production of these chimeric proteins was 
compatible with subviral particle assembly  and secretion. 
 
Materials and methods 
 
Semliki forest virus (SFV)-derived plasmids construction 
 
The plasmid pSFV-SHBs
adw
 (renamed here pSFV-S) encoding the small (S) envelope protein 
of a HBV subtype adw has been described elsewhere [23]. A second plasmid, pSFV-E1E2, 
containing the DNA fragment encoding the HCV E1 and E2 envelope proteins was designed 
from the previously described pSFV-HCV
dj
 plasmid (Genbank AF529293), encoding the 
core-E1-E2 sequence of a genotype 1a HCV [24]. This amplified HCV
dj
 DNA sequence also 
contained the upstream signal sequence responsible for translocation of the E1 ectodomain 
into the ER lumen (aa 166 to 191 from the HCV core protein in the HCV polyprotein) [25]. 
Briefly, the HCV
dj
 E1-E2 DNA sequence (corresponding to aa 166 to 746 in the HCV 
polyprotein) was amplified by PCR and inserted into the BamHI restriction site of a pSFV 
vector (Invitrogen). Using a proofreading Taq DNA polymerase (TaKaRA Ex Taq, Takara), 
we constructed by serial PCR amplification the pSFV-E1-S and pSFV-E2-S plasmids, 
encoding the chimeric HBV-HCV envelope proteins (Fig. 1). For  pSFV-E1-S, we first 
amplified a DNA fragment encoding a truncated form of the HBV S protein (aa 23 to 226) 
from pSFV-S, using a forward primer (regular typeface) flanked by an HCV “E1” sequence 
(italic) 5’-GCTGTTCGCCAGCACAAGAATCCTC-3’ and a reverse primer flanked by a 
BamHI restriction site sequence (underlined) 5’-
ATAGGATCCTTAAATGTATACCCAGAGACAAAGAAAAT-3’. The inserted stop codon 
is indicated in bold typeface. The same strategy was used to design the pSFV1-E2-S 
construct, with a forward primer flanked by the HCV “E2” sequence (italics) 5’-
GCTACTCATATCCCAAACAAGAATCCTCACAATACC-3’. We then amplified a DNA 
fragment encoding the HCV E1 protein from pSFV-E1E2, using a forward primer flanked by 
BamHI restriction site sequence 5’-ATAGGATCCATGACAGGGAACCTTCCTGGTTGC-3’ 
and a reverse primer flanked by HBV S sequence 5’-
TGAGGATTCTTGTGCTGGCGAACAGCAA-3’. The inserted start codon is indicated in bold 
typeface. This DNA fragment encoded aa 166 to 380 of the HCV polyprotein, including aa 
166 to 191 from the HCV core protein, serving as an ER translocation signal sequence for E1. 
The same strategy was used to amplify a DNA fragment encoding the HCV E2 protein, for 
the construction of pSFV-E2-S, with a forward primer flanked by the BamHI restriction site 
sequence 5’-ATAGGATCCATGGGGAACTGGGCGAAGGT-3’ and a reverse primer flanked 
by HBV S sequence 5’-GGTATTGTGAGGATTCTTGTTTGGGATATGAGTAGCA -3’. This 
DNA fragment encoded aa 366 to 743 of the HCV polyprotein, including aa 366 to 383 from 
the HCV E1 protein and serving as an ER translocation signal sequence for E2. The E1 and 
E2 proteins encoded by these constructs had 3 aa fewer at their C-terminal ends (aa 381 to 
383 for E1 and aa 744 to 746 for E2) than the wild-type proteins, to prevent cleavage of the 
chimeric proteins by the ER signal peptidases. Finally, a third PCR was used to connect the 
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sequence encoding E1 or E2 to the corresponding S DNA fragment. The PCR product was 
inserted into pGEM

-T (pGEM

-T Easy Vector System, Promega) and then into the BamHI 
restriction site of the pSFV vector (Invitrogen). All PCR products were verified by DNA 
sequencing. 
 
Analysis of BHK-21 cells transiently transfected with pSFV RNAs  
 
Recombinant Semliki RNA synthesis, BHK-21 cells (baby hamster kidney cells)  culture and 
transfection, and western-blot analysis were performed as previously described [23]. Briefly, 
for recombinant RNA synthesis, pSFV constructs were linearized by digestion at the single 
SpeI site. Linear plasmids were transcribed in vitro, using SP6 RNA polymerase, according to 
the standard protocol provided by the manufacturer (Promega). For the negative control, 
recombinant RNA encoding β-galactosidase (β-Gal) was synthesized from the pSFV3 
expression vector (Invitrogen). For western-blot analysis, the membranes were incubated 
overnight at 4 °C with a rabbit polyclonal antibody against HBsAg (R247) [26] or a mouse 
monoclonal antibody against E1 (A4) or against E2 (H52) [27]. For ultrastructural analysis by 
electron microscopy (EM), cells were fixed directly in the culture dish 16 hours after 
transfection, by incubation for 48 hours in 4 % paraformaldehyde and 1 % glutaraldehyde in 
0.1 M phosphate buffer pH 7.2.  Cells were scraped off with a Cell Scraper

 (Falcon), washed 
in PBS, post-fixed by incubation for 1 hour with 1 % osmium tetroxide and dehydrated in a 
graded series of ethanol solutions. Cell pellets were embedded in Epon resin (Sigma), which 
was allowed to polymerize for 48 hours at 60 °C. Ultrathin sections were cut, stained with 5 
% uranyl acetate and 5 % lead citrate, and deposited on EM grids coated with collodion 
membrane, for examination under a Jeol 1010 transmission electron microscope (TEM).  
 
For the analysis of intracellular subviral envelope particles, transfected BHK-21 cells 
were collected 16 h after transfection and treated as previously described [23]. Briefly, cells 
were lysed by heat shock  and homogenized for 10 minutes on ice. The samples were layered 
onto the top of a discontinuous sucrose gradient (25 to 60 % in 20 mM Tris pH 8), and 
centrifuged at 4 °C for 16 hours at 28,000 rpm in an SW 41 rotor (Beckman). The collected 
fractions were analyzed by immunocapture ELISA on plates coated with a mouse monoclonal 
antibody against S (H25B10, ATCC), and quantified using the biotinylated form of the 
H25B10 as a detection reagent. Sequential dilutions of a recombinant HBs Ag (HBs Ag adw 
R86872, BioDesign) were used as a standard. Positive fractions were pooled and dialyzed 
against 20 mM Tris pH 8 at 4 °C, and then concentrated with an Amicon
 
Ultracell-100k 
(Millipore) device. These crude preparations were further purified by anti-S affinity 
chromatography as previously described [23]. The final concentrated preparations were then 
deposited on carbon-coated EM grids, negatively stained with 1 % uranyl acetate, and 
analyzed in the TEM. They were also analyzed by western blotting, as for the cell lysates, as 
described above.  
 
Stable production of the wild-type HBV S and chimeric HBV-HCV envelope proteins in clones 
of the CHO cell line 
 
Chinese hamster ovary cells (CHO) cells were stably transduced using a strategy based on a 
lentiviral expression vector, with the pHR’ plasmid, described elsewhere [28], and generously 
provided by Didier Trono (Ecole Polytechnique Fédérale de Lausanne, Switzerland). The 
DNA sequence encoding the HBV S protein in pSFV-S plasmid was released and inserted 
into the BamHI restriction site of pHR’
hph
  (constructed from pHR’, containing the hph gene 
encoding hygromycin phosphotransferase), to generate pHR’
hph
-S. Lentiviruses were 
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produced in HEK-293T cells (human embryonic kidney cells), maintained in Dulbecco’s 
Modified Eagle Medium (DMEM). Twenty-four hours before transfection, 3 x 10
6
 cells were 
used to seed a 75-cm
2
 culture dish (Falcon). Cells were transfected with an equimolar mixture 
(1 pmol of each) of lentiviral pHR’
hph
-S, pHCMVG plasmid encoding the VSV-G (vesicular 
stomatitis virus envelope glycoprotein) and the packaging construct p8.74, by the calcium 
phosphate method. The following day, the transfection solution was removed and replaced 
with fresh complete medium. After 24 and 48 hours of culture, the supernatant was collected, 
filtered through a low-protein binding filter with 0.45-µm pores (Sartorius) and concentrated 
by centrifugation on a 20 % sucrose gradient at 4 °C for 90 minutes at 100,000 X g. The pellet 
was resuspended in 500 µl of PBS and stored at -80 °C until use. The unit of transduction 
(UT) titer was determined by quantifying p24 protein (Innotest HIV Antigen mAb Kit, 
Innogenetics). The DNA sequences of the pSFV-E1-S and pSFV-E2-S plasmids encoding the 
E1-S and the E2-S proteins, respectively, were transferred into the BamHI restriction site of 
the pHR’
gfp
 plasmid (constructed from pHR’, encoding  the GFP as a screening marker) by a 
similar strategy, to generate the pHR’
gfp
-E1-S and pHR’
gfp
-E2-S plasmids. Lentivirus particles 
were produced as described above. 
 
CHO cells in DMEM-F12 were first transduced with the recombinant HR’
hph
-S 
lentivector. One day before transduction, 10
5
 cells per well were used to seed in a six-well cell 
culture plate (Falcon). Cells were incubated with HR’
hph
-S vectors (multiplicity of infection : 
2.5) and 4 µg/ml polybrene (Sigma) in fresh complete medium. The following day, the 
transduction solution was removed, the cells were rinsed with PBS and then incubated for 48 
hours. They were then used to seed a 75-cm
2
 culture dish (Falcon) and incubated with 1 
mg/ml hygromycin (Euromedex) for 3 weeks. A hygromycin-resistant cell clone named 
CHO-S was isolated, using a cloning cylinder (Invitrogen), and amplified. This CHO-S clone 
was  then transduced with recombinant HR’
gfp
-E1-S or HR’
gfp
-E2-S lentivirus preparations, as 
described above. Three days after post-transduction, the cells were used to seed a 96-well cell 
culture plate (Falcon) at a density of 1 cell per well. The plates were incubated for 3 weeks. 
Two GFP-positive cellular clones - CHO-S+E1-S and CHO-S+E2-S - were amplified. The 
intracellular production of the HBV S, HBV-HCV chimeric E1-S and E2-S proteins was 
analyzed by the western blotting of the cell lysates, as described above for  BHK-21 cells. 
 
Analysis of the supernatant of CHO cells stably coproducing HBV S and chimeric HBV-HCV 
envelope proteins 
 
Secreted subviral envelope particles were purified from cell supernatants by centrifugation on 
a CsCl gradient, as previously described [29]. Briefly, 200 ml of supernatant was clarified and 
total protein precipitated by adding a 45 % solution of (NH
4
)
2
SO
4
 (pH7.5). The precipitate 
was collected by centrifugation at 4 °C for 15 minutes at 10,000 X g and the pellet was 
dissolved in a minimal volume of Tris-NaCl-EDTA buffer (TNE) (10 mM Tris/HCl pH 7.5 / 
100 mM NaCl / 1 mM EDTA). The solution was dialyzed against TNE buffer and CsCl was 
added to a density of 1.22 g/cm
3
. Two successive runs of isopycnic centrifugation were 
performed at 15 °C for 24 hours at 40,000 rpm in a 45Ti rotor (Beckman). Fractions were 
collected from the top and were assayed for HBsAg by ELISA, as described above. Peak 
fractions were pooled and dialyzed at 4 °C against TNE buffer. The final preparations were 
analyzed by negative staining and western blotting as described above. 
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Results 
 
Production of the HBV S, the HBV-HCV chimeric E1-S and E2-S proteins from an SFV vector 
in BHK-21 cells 
 
Sixteen hours after transfection with the recombinant SFV constructs encoding the S protein, 
the chimeric E1-S protein or E2-S protein, BHK-21 cells were harvested and lysed for 
western blot analysis (Fig. 2A). Consistent with our previous findings, the S protein was 
detected as its unglycosylated (p24) and glycosylated (p27) forms (23) which were produced 
in similar amounts.  The chimeric E1-S protein was detected at 54 kD, by both the anti-HBs 
rabbit polyclonal antibodies, and the anti-E1 monoclonal antibody (Fig. 2A). As an E1 
produced from an SFV construct containing the DNA sequence encoding the E1-E2 proteins 
migrated at 30 kD on the same blot, this band at 54 kD is consistent with the expected size of 
the chimeric E1-S protein. Previous studies have shown that the unglycosylated E1 protein 
migrates at 19 kD [30]. This suggests that our chimeric E1-S protein at 54 kD is glycosylated 
and therefore has the expected transmembrane topology, with the E1 ectodomain in the ER 
lumen.  The chimeric E2-S protein was detected at around 85 kD, by both the polyclonal anti-
HBs antibodies and the monoclonal anti-E2 antibody (Fig. 2A). As E2 produced from an SFV 
construct containing the DNA sequence encoding the E1-E2 proteins migrated at 65 kD, this 
band around 85 kD is consistent with the expected size of the chimeric E2-S protein. Previous 
studies have shown that an unglycosylated form of E2 migrates at 38 kD [31]. As above, this 
suggests that our chimeric 85 kD E2-S protein is also glycosylated, thus retaining the 
expected transmembrane topology, with the E2 ectodomain in the ER lumen. Although the 
anti-HBs and anti-E2 antibodies gave a weak signal for the chimeric proteins as compared to 
the wild-type proteins, the anti-E1 antibody detected efficiently the E1-S chimeric protein. 
This suggests that the E1-S chimeric protein was produced at a good level and that its weak 
detection by the anti-S was more related to a poor recognition by the antibody than its 
expression level. 
 
Ultrastructural changes induced by the production of HBV S or of the HBV-HCV chimeric 
E1-S and E2-S proteins from a SFV vector in BHK-21 cells 
 
Sixteen hours after transfection with the recombinant SFV constructs encoding the S protein, 
the chimeric E1-S protein or the chimeric E2-S protein, BHK-21 cells were investigated by 
EM. Consistent with our previous findings [23], cells producing the S protein displayed 
significant ultrastructural modifications on EM, with respect to the cells producing β-Gal 
(Fig. 2B). Intracellular vesicles packed with HBV subviral filaments, were abundant in the 
perinuclear area of these cells (Fig. 2B). We have previously demonstrated that these 
filaments act as the precursor of spherical HBV subviral envelope particles [23]. However, 
despite intensive observation and repeated experiments, no ultrastructural changes and no 
filaments were observed in the cells producing the E1-S or E2-S proteins, suggesting that 
these chimeric proteins were unable to self-assemble into subviral filaments. 
 
Cotransfection of BHK 21 cells with the recombinant SFV constructs containing DNA 
sequences encoding the S and chimeric E1-S or E2-S proteins, and purification and analysis 
of the intracellular HBV subviral fiaments 
 
Initial analysis by negative EM staining of the crude BHK-21 cell lysates subjected to 
centrifugation on a sucrose gradient led to the observation of long subviral filaments 22 nm in 
diameter and frequently branched, as previously described [23] (data not shown). These 
7 
filaments were purified by affinity chromatography with anti-HBs antibody. They were then 
systematically unbranched, and their ends tended to dissociate into subviral spherical particles 
(Fig. 3A), as previously described [23]. Western blots of purified subviral filaments showed 
that the filaments induced by production of the S and E1-S proteins together contained both 
the wild-type S protein (p24 and p27, Fig. 3B) and the E1-S chimeric protein (p54, Fig. 3B) 
which was detected by both anti-HBs polyclonal antibodies and the anti-E1 monoclonal 
antibody. The chimeric E1-S protein was therefore efficiently incorporated into intracellular 
HBV subviral filaments. However, it was more difficult to observe the incorporation of the 
E2-S protein into the filaments obtained following the production of the S and E2-S proteins 
together, as p85 was barely detectable with both polyclonal anti-HBs and monoclonal anti-E2 
antibodies (data not shown).  
 
Coproduction of the chimeric E1-S or E2-S proteins with the wild-type HBV S protein in 
stably transduced CHO cells 
 
Western blot analysis of a lysate of the CHO cells stably producing the HBV S protein (CHO-
S) showed a high intracellular concentration of p24 and p27 (Fig. 4). Similar intracellular 
levels of HBV S protein were observed in the two CHO subclones obtained by transduction of 
the parental CHO-S cell line with lentiviral constructs encoding E1-S or E2-S (subclones 
CHO-S+E1-S and CHO-S+E2-S, respectively). In addition, large amounts of intracellular E1-
S protein (p54) were detected with the anti-E1 antibody in the CHO-S+E1-S subclone, and a 
large amounts of intracellular E2-S protein (p85) were detected with the anti-E2 antibody in 
the CHO-S+E2-S subclone (Fig. 4). Thus, we were able to establish two clones of the CHO 
cell line that continuously produce the HBV S protein together with either the E1-S or the E2-
S chimeric HBV-HCV envelope protein. 
 
Purification and analysis of the HBV subviral particles released into the supernatant of the 
CHO-S, CHO-S+E1-S and CHO-S+E2-S clones 
 
The supernatants of the three clones were found to contain similar amounts of HBs Ag 
(around 100 ng/ml, determined by ELISA), and these amounts remained stable over time 
during passages of the different clones (58
th
 passage at this time). The supernatant (200 ml) of 
these 3 clones was subjected to protein precipitation and centrifugation on an isopycnic CsCl 
gradient. We collected 20 fractions from the bottom of the gradient and tested them 
individually for HBsAg by ELISA (Fig. 5A). For all the three clones, fraction 9 (1.18 g/cm
3 
in 
CsCl) corresponded to the peak fraction for HBsAg levels in the supernatant. Fractions 8, 9 
and 10 of each of the 3 clones were pooled and dialyzed, before further analysis by negative 
EM staining and western blotting. EM analysis demonstrated that these 3 supernatants 
contained spherical HBV subviral particles. The subviral particles present in the supernatant 
of the CHO-S+E1-S and CHO-S+E2-S clones were similar in size (about 22 nm in diameter) 
and shape to the subviral particles present in the supernatant of the CHO-S cell line producing 
the wild-type HBV S protein (Fig. 5B). A sample corresponding to one microgram of HBs Ag 
(determined by ELISA) for each of the three preparations was subjected to western blotting 
with the polyclonal anti-HBS and the monoclonal anti-E1 and anti-E2 antibodies, as described 
above. The HBV S protein was detected in the form of p24 and p27 in all three preparations 
(Fig. 5C). The amount of p24 was higher than for p27 in the purified subviral particles, as 
observed in previous studies (5, 9). Moreover, significant amounts of E1-S protein (p54) and 
E2-S protein (p85) were detected with anti-E1 and anti-E2 antibodies in the samples 
corresponding to the CHO-S+E1-S and CHO-S+E2-S clones, respectively (Fig. 5C). Thus, 
the chimeric E1-S and E2-S proteins were efficiently incorporated into the spherical HBV 
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subviral particles stably secreted by the CHO-S+E1-S and CHO-S+E2-S subclones. 
Moreover, these chimeric HBV-HCV envelope subviral particles were similar in appearance 
to the wild-type HBV envelope subviral particles. 
 
Discussion  
 
For optimal immunogenicity, epitopes should ideally be presented as several copies on a 
defined particulate structure. HBV subviral envelope particles are used worldwide in the form 
of commercial vaccines for hepatitis B prevention. Based on their particulate structure and 
intrinsic immunogenic potential, these particles have also been thoroughly investigated as a 
possible carrier matrix for foreign epitopes exposition. For such strategies, the external 
hydrophilic loop of the HBV S protein is the preferred site of insertion [16], but many studies 
have also reported the insertion of foreign protein sequences at the N-terminus or C-terminus 
of the HBV S protein, as the ends of the protein are also exposed at the surface of the subviral 
particle. We report here another strategy leading to the insertion of foreign protein sequences 
at the HBV S N-terminus and demonstrate, for the first time, that the N-terminal 
transmembrane domain of the HBV S protein may be replaced by the transmembrane domain 
of a foreign protein, to generate a chimeric protein suitable for assembly into and secretion as 
a subviral particle. Indeed, although our chimeric HBV-HCV envelope proteins S-E1 and S-
E2 were unable to self-assemble into a subviral particle on their own, these proteins were 
efficiently assembled into subviral particles when produced together with the wild-type HBV 
S protein. We made use of our recently established model of HBV S production with an SFV 
vector [23], which constitutes a powerful tool for studying the assembly or coassembly 
properties of modified HBV S proteins. Most previous studies focusing on the assembly of 
HBV S mutants were limited to investigation of the release of these mutants into the cell 
supernatant [17, 32], without determining whether complete or partial defects were due to the 
impairment of assembly or secretion.  
 
Our study of HBV-HCV chimeric proteins shows that the HBV S N-terminal 
hydrophobic region is remarkably tolerant to sequence substitutions preserving its ability to 
assemble into subviral envelope particles. Previous studies have demonstrated that the N-
terminal hydrophobic region of S (aa 8 to 22) is a type I signal sequence not cleaved by signal 
peptidase. This domain seems to be sensitive to mutations as it is not possible to delete even 
part of this sequence without deleterious effects on the assembly and secretion of subviral 
envelope particles [17, 32]. An HBV S mutant lacking amino acids 9 to 22 cannot self-
assemble or assemble with the wild-type HBV S [33]. As demonstrated by efficient 
glycosylation, the second hydrophilic domain of this mutant was translocated across the ER 
membrane but remained arrested in a membrane-associated configuration. Targeting to and 
anchoring in the ER membrane were probably mediated by the second hydrophobic 
transmembrane domain of S (aa 80 to 98), corresponding to a type II signal. In another study, 
a chimeric protein consisting of the β-lactamase signal sequence, the α-globin and the HBV S 
protein deleted of its N-terminal transmembrane domain was constructed [32]. This chimeric 
protein was not secreted on its own, but was secreted into the culture medium in very small 
amounts if produced together with the wild-type HBV S protein. The authors suggested that 
the N-terminal transmembrane domain of HBV S might not be absolutely essential for  
coassembly and cosecretion with the wild-type HBV S protein [32]. Our results are consistent 
with those of this previous study, although our chimeric HBV-HCV envelope proteins seemed 
to be efficiently coassembled and secreted with the HBV S protein. It remains unclear 
whether this efficient coassembly was due the specific contribution of the HCV E1 or E2 
transmembrane domains. Lipids account for only 25 % by weight of the HBV subviral 
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particle [34], and are therefore unlikely to be organized into a conventional membrane bilayer. 
Instead, lipid reorganization and tight lateral interaction between protein subunits are 
probably required for subviral particle formation [13]. It would be interesting to determine in 
the future whether coassembly is equally efficient with other foreign transmembrane proteins. 
This is of importance, as similar strategies with other foreign proteins could lead to new 
vaccine strategies for other infectious agents, based on vaccine candidates produced with the 
same industrial procedures used for the HBV vaccine. Our model of HBV S production with 
an SFV vector could be very useful for screening various chimeric proteins for their 
coassembly properties with the wild type HBV S protein.  
 
We were here able to establish clones of the CHO cell line stably producing high 
levels of the HBV S together with the chimeric HBV-HCV S-E1 or S-E2 proteins. CHO is a 
relevant cell line as it is widely used for medicinal recombinant protein production. The 
subviral envelope particles secreted by these two clones were similar to the wild-type HBV S 
subviral particles and contained large amounts of chimeric HBV-HCV S-E1 or S-E2 proteins. 
Thus, the entire HCV E1 or E2 envelope protein, including the ectodomain and 
transmembrane domain can be incorporated in large amount into subviral envelope particles 
resembling the HBV vaccine. The ectodomains of E1 and E2 are presented at the surface of 
these subviral particles, as shown by the size of these chimeric proteins in the purified 
particles, consistent with the expected glycosylation pattern. As previous studies have shown 
that HCV envelope proteins lacking their transmenbrane domain have impaired antigenic and 
functional properties [22], our chimeric HBV-HCV subviral envelope particles may open new 
possibilities for testing the entire HCV E1 and E2 proteins (individually or as a mixture) for 
original vaccination strategies. Our study may also have implications for the design of new 
vaccine candidates based on the use of the HBV subviral particle as a carrier for various 
transmembrane proteins from other infectious agents. 
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Fig1. Transmembrane topology of the wild-type HBV S and HCV E1 and E2 envelope 
proteins and of the HBV-HCV E1-S and E2-S chimeric proteins used in this study. The boxes 
indicate the hydrophobic domains of these proteins, anchored in the ER membrane. Assembly 
refers to the ability of the HBV S or the HBV-HCV chimeric proteins to self-assemble into a 
subviral envelope particle. Coassembly with HBV S refers to the ability of the HBV-HCV 
chimeric proteins to coassemble with the wild-type HBV S into a subviral envelope particle, 
following the production of the chimeric protein together with the HBV S-protein. 
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Fig2. Analysis of the HBV and HCV wild-type envelope proteins and HBV-HCV chimeric 
protein production within BHK-21 cells transfected with the various pSFV constructs, by 
western blotting (A) and electron microscopy (B). A : Western blots probed with polyclonal 
anti-HBs antibodies showed that transfection with the pSFV-S construct led to production of 
the unglycosylated (p24) and glycosylated (p27) forms of the HBV S protein. Western blots 
probed with anti-E1 and anti-E2 monoclonal antibodies showed that transfection with pSFV-
E1E2 led to production of the HCV E1 (p30) and E2 (p65) proteins. Cell transfection with 
14 
pSFV-E1-S led to the production of a 54 kD protein, recognized by both anti-HBs and anti-E1 
antibodies with the expected size of  the chimeric E1-S protein. The transfection of cells with 
pSFV-E2-S led to the production of a protein at 85 kD that was recognized by both anti-HBs 
and anti-E2 antibodies and had the expected size of the chimeric E2-S protein. BHK-21 cells 
transfected with pSFV-β-gal were used as controls. Molecular weight markers (M) are 
indicated on the left of the blots.  B : BHK-21 cells producing the wild-type HBV S protein 
were characterized by the presence of numerous vesicles 0.2 to 0.3 mm in diameter (white 
arrows), packed with 22 nm large subviral filaments (enlarged view in the inset) in the 
perinuclear area. No specific ultrastructural changes were observed in cells producing β-Gal, 
the chimeric E1-S, the chimeric E2-S, or the E1 and E2 HCV envelope proteins (not shown 
on the figure). In these cells, no particular change in the ER compartment (black arrows) 
could be identified. Bars: 1 micrometer (for S), 0.2 micrometers (for β-gal), 50 nanometers 
(for E1-S), 100 nm (for E2-S).  
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Fig 3. Purification by affinity chromatography and analysis by negative EM staining (A) and 
western blotting (B) of the intracellular subviral filaments recovered from BHK-21 cells 
transfected with the pSFV-S construct or cotransfected with the pSFV-S and pSFV-E1-S 
constructs. A : Long filaments with a diameter of 22 nm dissociating into subviral spherical 
particles at their ends were observed in both cases (bars : 100 nm). B : Subviral filaments 
recovered from cells producing the HBV S protein (S fil.) were rich in S protein, as shown by 
the large amount of p24 and p27 detected in these filaments with anti-HBs antibodies.  
Subviral filaments recovered from cells producing both HBV S and the chimeric E1-S 
proteins (S+E1-S fil.) were also rich in S protein, as the same bands were identified with anti-
HBs antibodies. These filaments also contained the E1-S (p54) protein, which was recognized 
by both anti-HBs and anti-E1 antibodies. Lysates (cell ly.) of BHK-21 cells transfected with 
pSFV-E1E2 or pSFV-β-gal were used as controls 
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Fig4. Western blot of HBV S production in a CHO clone stably transfected with a lentiviral 
construct encoding HBV S (CHO-S), and of HBV-HCV chimeric proteins produced in two 
derived subclones (CHO-S+E1-S and CHO-S+E2-S) stably cotransfected with lentiviral 
constructs encoding the chimeric E1-S or E2-S proteins. All CHO clones displayed similar 
levels of HBV S protein production, in the form of p24 and p27, as revealed with polyclonal 
anti-HBs antibodies.  The CHO-S+E1-S subclone produced a p54 kD protein recognized by 
the anti-E1 monoclonal antibody and corresponding to the E1-S chimeric protein. The CHO-
S+E2-S subclone produced a p85 kD protein recognized by the anti-E2 monoclonal antibody, 
and corresponding to the E2-S chimeric protein. Untransfected CHO cells were used as 
control. 
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Fig5. Analysis of the subviral envelope particles secreted into the supernatant of the CHO-S, 
CHO-S+E1-S or CHO-S+E2-S clones, by CsCl gradient centrifugation (A), negative EM 
staining (B) and western blotting (C). A: For the three supernatants, HBs Ag concentration, as 
determined by ELISA, peaked in fractions 8, 9 and 10. B:  Negative EM staining performed 
after the pooling and dialysis of fractions 8-9-10 for the three supernatants demonstrated the 
presence of similar 22 nm-diameter spherical subviral envelope particles. C : All preparations 
18 
contained similar amounts of HBV S protein, in the form of p24 and p27, detected with 
polyclonal anti-HBs antibodies. The S+E1-S particles contained the p54 kD protein, which 
was recognized by the anti-E1 monoclonal antibody and corresponded to the E1-S chimeric 
protein. The S+E2-S particles contained the p85 kD protein recognized by the anti-E2 
monoclonal antibody, corresponding to the E2-S chimeric protein. 
